Interim Results from the International Trial of Second Sight's Visual Prosthesis

Doheny Eye Institute, University of Southern California, Los Angeles, California, USA.
Ophthalmology (Impact Factor: 6.17). 01/2012; 119(4):779-88. DOI: 10.1016/j.ophtha.2011.09.028
Source: PubMed

ABSTRACT This study evaluated the Argus II Retinal Prosthesis System (Second Sight Medical Products, Inc., Sylmar, CA) in blind subjects with severe outer retinal degeneration.
Single-arm, prospective, multicenter clinical trial.
Thirty subjects were enrolled in the United States and Europe between June 6, 2007, and August 11, 2009. All subjects were followed up for a minimum of 6 months and up to 2.7 years.
The electronic stimulator and antenna of the implant were sutured onto the sclera using an encircling silicone band. Next, a pars plana vitrectomy was performed, and the electrode array and cable were introduced into the eye via a pars plana sclerotomy. The microelectrode array then was tacked to the epiretinal surface.
The primary safety end points for the trial were the number, severity, and relation of adverse events. Principal performance end points were assessments of visual function as well as performance on orientation and mobility tasks.
Subjects performed statistically better with the system on versus off in the following tasks: object localization (96% of subjects), motion discrimination (57%), and discrimination of oriented gratings (23%). The best recorded visual acuity to date is 20/1260. Subjects' mean performance on orientation and mobility tasks was significantly better when the system was on versus off. Seventy percent of the patients did not have any serious adverse events (SAEs). The most common SAE reported was either conjunctival erosion or dehiscence over the extraocular implant and was treated successfully in all subjects except in one, who required explantation of the device without further complications.
The long-term safety results of Second Sight's retinal prosthesis system are acceptable, and most subjects with profound visual loss perform better on visual tasks with system than without it.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Millions of people worldwide face partial or total vision loss due to inherited photoreceptor degenerative diseases, which currently have no cure. Retinal prostheses have been developed to restore vision by electrically stimulating surviving retinal neurons, but have low spatial resolution and nonselectively stimulate retinal ganglion cell (RGC) axons along with somata. We propose a biomimetic solution: using the neurotransmitter glutamate to chemically stimulate RGCs to avoid the disadvantages of electrical stimulation. Our results demonstrate that glutamate stimulation has a spatial resolution comparable to current-generation electrical prostheses, can stimulate RGC somata without stimulating axons, and can produce spatially differential responses in RGC subtypes. These results highlight the benefits of a neurotransmitter-based retinal prosthesis over current-generation electrical prostheses.
  • [Show abstract] [Hide abstract]
    ABSTRACT: A novel multifunctional and biocompatible ultrananocrystalline diamond (UNCD) film technology developed recently represents a new material with a unique combination of functionalities, including biocompatibility, to enable a new generation of implantable medical devices and scaffolds for tissue engineering. Following a description of the synthesis and properties of UNCD films and a comparison with other diamond film technologies, this article focuses on descriptions of key UNCD-based medical devices to treat specific medical conditions requiring effective therapies: (1) A UNCD-coated microchip (artificial retina) implantable inside the eye on the retina to restore partial vision to people blinded by retinitis pigmentosa and macular degeneration produced by genetically induced degeneration of the retina photoreceptors. (2) A UNCD-coated intraocular device for treatment of glaucoma in the eye. (3) UNCD-coated metal dental implants with potential order of magnitude longer life and superior performance than current implants.
    MRS Bulletin 07/2014; 39(07):621-629. DOI:10.1557/mrs.2014.134 · 5.07 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Millions of patients are either slowly losing their vision or are already blind due to retinal degenerative diseases such as retinitis pigmentosa (RP) and age-related macular degeneration (AMD) or because of accidents or injuries. Employment of artificial means to treat extreme vision impairment has come closer to reality during the past few decades. Currently, many research groups work towards effective solutions to restore a rudimentary sense of vision to the blind. Aside from the efforts being put on replacing damaged parts of the retina by engineered living tissues or microfabricated photoreceptor arrays, implantable electronic microsystems, referred to as visual prostheses, are also sought as promising solutions to restore vision. From a functional point of view, visual prostheses receive image information from the outside world and deliver them to the natural visual system, enabling the subject to receive a meaningful perception of the image. This paper provides an overview of technical design aspects and clinical test results of visual prostheses, highlights past and recent progress in realizing chronic high-resolution visual implants as well as some technical challenges confronted when trying to enhance the functional quality of such devices.
    Journal of Ophthalmic & Vision Research 10/2014; 9(4):494. DOI:10.4103/2008-322X.150830

Full-text (2 Sources)

Available from
Jun 4, 2014